In This Article:
Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop new small molecule therapies.
The deal will utilise the advanced AI technologies of Genesis to generate therapeutic candidates for targets chosen by Gilead.
Genesis’ field-leading AI platform, Genesis Exploration of Molecular Space (GEMS) will be used in the partnership to aid in creating and streamlining molecules for the Gilead-chosen targets.
The collaboration will focus on preclinical research, with Gilead holding sole rights for the clinical development and potential commercialisation of the compounds developed.
Gilead Sciences Research executive vice-president Flavius Martin stated: “The use of generative AI in drug development, enabled by people, science and other new technology, has shown potential to accelerate the discovery of molecules for challenging targets.
“We look forward to working with Genesis to apply their AI platform to discover and advance novel therapies that may address significant unmet patient needs.”
Genesis is entitled to receive $35m in upfront payment for three targets, with options for Gilead to nominate additional targets for a fee.
Genesis also stands to gain further financial rewards through preclinical, development, regulatory and commercial milestones, as well as royalty payments on net product sales.
Genesis founder and CEO Evan Feinberg stated: “Many promising protein targets have a paucity of relevant training data, which makes it difficult to apply off-the-shelf machine learning methods.
"We have designed our physical AI platform to address this issue and enable drug discovery campaigns for difficult targets. Genesis is thrilled to combine our expertise in generative AI and drug discovery with Gilead’s deeply experienced research and development teams, with the shared goal of creating breakthrough therapies for patients.”
Genesis had previously secured more than $300m in funding to create a pipeline, targeting high-impact medical conditions.
The latest development comes after Gilead partnered with PANTHERx Rare to distribute LIVDELZI, a treatment for adults with primary biliary cholangitis.
"Gilead and Genesis partner to create novel therapies using AI" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.